Current Report Filing (8-k)
February 18 2020 - 8:50AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
February 14, 2020
Date of report (Date of earliest event reported)
Agile Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36464
|
|
23-2936302
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
101 Poor Farm Road
Princeton, New Jersey
(Address of principal executive offices)
|
|
08540
(Zip Code)
|
Registrant’s telephone number, including
area code (609) 683-1880
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
AGRX
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item
|
7.01 Regulation FD Disclosure
|
On February 14, 2020, Agile Therapeutics,
Inc. (the “Company”) issued a press release announcing that on February 14, 2020, the U.S. Food and Drug Administration
(“FDA”) approved Twirla as a method of contraception for use in women of reproductive potential with a BMI < 30
kg/m2 for whom a combined hormonal contraceptive is appropriate. The Company is furnishing herewith a copy of the press
release, which is attached hereto as Exhibit 99.1.
In accordance with General Instructions
B.2 and B.6 of Form 8-K, the information included in this Item 7.01 (including Exhibit 99.1 attached hereto), shall not be
deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any
filing made by the Company under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference
in such a filing.
|
Item
|
9.01. Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Agile Therapeutics, Inc.
|
|
|
|
Dated: February 18, 2020
|
By:
|
/s/ Alfred Altomari
|
|
Name: Alfred Altomari
|
|
Title: Chairman and Chief Executive Officer
|
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024